David E Szymkowski Selected Research

XENP 1595

1/2019	Topical Administration of a Soluble TNF Inhibitor Reduces Infarct Volume After Focal Cerebral Ischemia in Mice.
12/2017	Inhibition of TNF reduces mechanical orofacial hyperalgesia induced by Complete Freund's Adjuvant by a TRPV1-dependent mechanism in mice.
4/2017	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia.
1/2016	Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination.
12/2014	Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia.
9/2014	Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice.
2/2013	Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis.
9/2011	Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination.
4/2009	Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guérin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David E Szymkowski Research Topics

Disease

11	Inflammation (Inflammations) 01/2019 - 12/2006
4	Infections 03/2017 - 04/2009
4	Autoimmune Diseases (Autoimmune Disease) 07/2014 - 08/2007
4	Rheumatoid Arthritis 07/2014 - 12/2009
3	Multiple Sclerosis 01/2016 - 09/2011
2	Infarction (Infarctions) 01/2019 - 12/2014
2	Brain Ischemia (Cerebral Ischemia) 01/2019 - 12/2014
2	Stroke (Strokes) 01/2019 - 12/2014
2	Pain (Aches) 12/2017 - 01/2016
2	Hypersensitivity (Allergy) 12/2017 - 03/2012
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2016 - 09/2011
2	Necrosis 09/2011 - 09/2011
2	Colonic Neoplasms (Colon Cancer) 09/2002 - 03/2002
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2019
1	Ischemic Stroke 01/2019
1	Facial Pain (Myofacial Pain) 12/2017
1	Hyperalgesia 12/2017
1	Demyelinating Diseases (Demyelinating Disease) 04/2017
1	Central Nervous System Infections (Central Nervous System Infection) 03/2017
1	Epilepsy (Aura) 03/2017
1	Seizures (Absence Seizure) 03/2017
1	Gout 01/2016
1	Nervous System Diseases (Neurological Disorders) 01/2016
1	Disease Progression 01/2016
1	Spinal Cord Injuries (Spinal Cord Injury) 09/2014
1	Encephalomyelitis (Myeloencephalitis) 05/2014
1	Tetanus 05/2014
1	Pathologic Processes 05/2014
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2013
1	Colitis 02/2013
1	Asthma (Bronchial Asthma) 04/2012
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 04/2012
1	Eosinophilia 10/2011
1	Pneumonia (Pneumonitis) 10/2011
1	Hyperplasia 10/2011
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2011
1	Granuloma 12/2010
1	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2009
1	Neoplasms (Cancer) 12/2009
1	Osteoporosis 12/2009
1	Arthritis (Polyarthritis) 08/2007
1	Idiopathic Pulmonary Fibrosis 12/2006
1	Fibrosis (Cirrhosis) 12/2006
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2006
1	Parkinson Disease (Parkinson's Disease) 09/2006
1	Neuroinflammatory Diseases 09/2006
1	Colorectal Neoplasms (Colorectal Cancer) 09/2002
1	Neoplasm Metastasis (Metastasis) 03/2002

Drug/Important Bio-Agent (IBA)

9	XENP 1595IBA 01/2019 - 04/2009
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 09/2006
6	Tumor Necrosis Factor InhibitorsIBA 01/2019 - 09/2006
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 05/2013
5	CytokinesIBA 10/2011 - 09/2002
4	Etanercept (Enbrel)FDA Link 01/2019 - 04/2009
3	Messenger RNA (mRNA)IBA 12/2017 - 01/2016
2	Biological ProductsIBA 12/2017 - 03/2012
2	Type I Tumor Necrosis Factor ReceptorsIBA 03/2017 - 01/2016
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 03/2017 - 09/2011
2	Type II Tumor Necrosis Factor ReceptorsIBA 03/2017 - 01/2016
2	Peptides (Polypeptides)IBA 07/2014 - 05/2014
2	Immunoglobulin E (IgE)IBA 04/2012 - 10/2011
2	AntigensIBA 10/2011 - 09/2011
2	LigandsIBA 01/2011 - 12/2009
2	EndotoxinsIBA 12/2010 - 04/2009
1	Freund's AdjuvantIBA 12/2017
1	CuprizoneIBA 04/2017
1	Glutamate Receptors (Glutamate Receptor)IBA 03/2017
1	MicroRNAs (MicroRNA)IBA 01/2016
1	Uric Acid (Urate)IBA 01/2016
1	InflammasomesIBA 01/2016
1	Polymethyl Methacrylate (Sol)IBA 12/2014
1	Fc Receptors (Fc Receptor)IBA 07/2014
1	Immunoglobulin M (IgM)IBA 05/2014
1	Immunoglobulin G (IgG)IBA 05/2014
1	B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA 05/2014
1	Abatacept (Orencia)FDA Link 05/2013
1	Immunosuppressive Agents (Immunosuppressants)IBA 05/2013
1	IgE Receptors (Fc epsilon RI)IBA 04/2012
1	Omalizumab (Xolair)FDA Link 04/2012
1	OvalbuminIBA 10/2011
1	Methacholine Chloride (Methacholine)FDA Link 10/2011
1	NF-kappa B (NF-kB)IBA 09/2011
1	Glucose (Dextrose)FDA LinkGeneric 09/2011
1	Phosphotransferases (Kinase)IBA 09/2011
1	Interleukin-4 (Interleukin 4)IBA 04/2011
1	CalciumIBA 04/2011
1	BCG lipopolysaccharideIBA 12/2010
1	AntibodiesIBA 04/2009
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 08/2007
1	Bleomycin (Blenoxane)FDA LinkGeneric 12/2006
1	LipopolysaccharidesIBA 09/2006
1	phorbolIBA 09/2002
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2002
1	Phenobarbital (Luminal)FDA Link 03/2002
1	RNA (Ribonucleic Acid)IBA 03/2002
1	MucinsIBA 03/2002

Therapy/Procedure

8	Therapeutics 01/2016 - 04/2009
1	Topical Administration 01/2019
1	Drug Therapy (Chemotherapy) 03/2017